Cabasso V J
Am J Hosp Pharm. 1976 Jan;33(1):48-51.
The development of rabies immune globulin of human origin is discussed. Antirabies serum of equine origin when used in conjunction with rabies vaccine, enhances significantly the chances of survival after a severe bite by a rabid animal. However, those who receive the equine serum may develop serum sickness or even anaphylaxis. To circumvent this risk, while preserving the benefit, many workers have attempted to develop rabies immune globulin of human origin. Success was impeded by the difficulty in obtaining rabies immune plasma with the needed antibody level. Despite this and other obstacles, production of the human globulin on a scale sufficient to satisfy clinical needs has been finally realized. At the appropriate dosage, this globulin was demonstrated to interfere minimally, if at all, with the expression of active immunity induced by vaccination.
本文讨论了人源狂犬病免疫球蛋白的研发情况。马源抗狂犬病血清与狂犬病疫苗联合使用时，可显著提高被狂犬严重咬伤后存活的几率。然而，接受马血清的人可能会发生血清病甚至过敏反应。为规避此风险并保留其益处，许多研究人员试图研发人源狂犬病免疫球蛋白。获取具有所需抗体水平的狂犬病免疫血浆存在困难，这阻碍了研发进程。尽管存在这一及其他障碍，但最终还是实现了足以满足临床需求规模的人源球蛋白生产。在适当剂量下，该球蛋白被证明即使有影响，也对疫苗诱导的主动免疫表达干扰极小。
